Respiratory failure among patients with COVID-19 in Jiangsu province, China: a multicentre retrospective cohort study

Wang, Y; Luo, Hang; Liu, S; Tang, Hao; Mortimer, Kevin; Yang, Yi; Wang, Duolao; Ju, Shenghong

doi:10.1017/s0950268821000157

Cited by 2 publications

(1 citation statement)

References 39 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are studies showing signi cant differences in selected demographic, epidemiological, clinical, and laboratory characteristics, as well as radiological features at admission and hospitalization, between patients with respiratory failure and those without respiratory failure. In patients with COVID-19, older age, a higher respiratory rate, a lower lymphocyte count and a higher pulmonary turbidity score on admission are independent risk factors for respiratory failure [10] . It was suggested that the severity of the host response to COVID-19 may be mainly due to the abnormal activation of peripheral blood neutrophils [11] .…”

Section: Discussionmentioning

confidence: 98%

Clinical Characteristics of Diabetic Patients with COVID-19 During the Full Liberalization of the Pandemic

Zhuang,

Li,

Sun

et al. 2024

Preprint

View full text Add to dashboard Cite

Diabetes is an important comorbidity of COVID-19. This study aimed to compare the clinical course and outcomes of COVID-19 patients with and without diabetes. We enrolled 321 hospitalized patients with COVID-19 from the Third Xiangya Hospital (Hunan, China) between December 20, 2021, and March 1, 2021, including 158 patients with diabetes and 163 patients without diabetes. Data from medical records, including clinical characteristics, coexisting conditions, complications, laboratory tests, radiographic studies, treatments and outcomes, were extracted and analyzed. Among COVID-19 patients with type 2 diabetes, several biochemical parameters, such as systolic blood pressure [137.00 (IQR: 122.00-148.50) vs. 126.00 (IQR: 116.00-137.00), P<0.001], CRP [64.25 (IQR: 28.16-129.83) vs. 44.13 (IQR: 17.56-87.26), P = 0.005], PCT [0.11 (IQR: 0.06-0.44) vs. 0.08 (IQR : 0.05-0.14), P = 0.002], urea nitrogen [15.40 (IQR 10.62-24.44) vs. 10.34 (IQR:7.56-15.14), P < 0.001), In terms of clinical symptoms, patients with diabetes had pleural effusion [17.3% vs. 7.5%, P=0.010], fever [39.0% vs. 60.7%, P<0.001], and nausea and vomiting [10.4% vs. 1.2%, P<0.001], and fatigue symptoms [22.7% vs 12.9%, P=0.022]. There were significant differences in comorbidities, including hypertension (71.2% vs. 37.0%, P<0.001) and chronic kidney disease (6.4% vs. 18.5%, P=0.001). The statistically significant difference in treatment between COVID-19 patients with diabetes and those without diabetes was mainly reflected in the use of azvudine (15.9% vs. 40.7%, P<0.001). Regression analysis revealed that the lymphocyte ratio (0R=0.925, 95% CI 0.885-0.966, P<0.001) and age (0R=1.025, 95% CI 1.003-1.048, P=0.027) had a statistically significant effect on the severity of respiratory failure. Some clinical symptoms and medication differences had statistically significant effects on survival time, including calcification (HR=0.410, 95% CI 0.193-0.872, P=0.021), pleural effusion (HR=1.935, 95% CI 1.259-2.975, P=0.003), diabetes (HR=1.416, 95% CI 1.042-1.926, P=0.026), chronic kidney disease (HR=1.557, 95% CI 1.032-2.349, P=0.035), use of antibiotics (HR=1.623, 95% CI 1.139-2.315, P=0.007) and glucocorticoids (HR=1.623, 95% CI 1.139-2.315, P=0.005), and use of mechanical ventilation (HR=4.201, 95% CI 1.883-9.377, P<0.001). Our study suggested that COVID-19 patients with diabetes tend to have more severe disease and poorer clinical outcomes, and this relationship requires further exploration.Retrospectively registered.

show abstract

Section: Discussionmentioning

confidence: 98%

Clinical Characteristics of Diabetic Patients with COVID-19 During the Full Liberalization of the Pandemic

Zhuang,

Li,

Sun

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

This systematic review and meta-analysis synthesized the evidence on the impacts of demographics and comorbidities on the clinical outcomes of COVID-19, as well as the sources of the heterogeneity and publication bias of the relevant studies. Two authors independently searched the literature from PubMed, Embase, Cochrane library, and CINAHL on 18 May 2021; removed duplicates; screened the titles, abstracts, and full texts by using criteria; and extracted data from the eligible articles. The variations among the studies were examined by using Cochrane, Q.; I2, and meta-regression. Out of 11,975 articles that were obtained from the databases and screened, 559 studies were abstracted, and then, where appropriate, were analyzed by meta-analysis (n = 542). COVID-19-related severe illness, admission to the ICU, and death were significantly correlated with comorbidities, male sex, and an age older than 60 or 65 years, although high heterogeneity was present in the pooled estimates. The study design, the study country, the sample size, and the year of publication contributed to this. There was publication bias among the studies that compared the odds of COVID-19-related deaths, severe illness, and admission to the ICU on the basis of the comorbidity status. While an older age and chronic diseases were shown to increase the risk of developing severe illness, admission to the ICU, and death among the COVID-19 patients in our analysis, a marked heterogeneity was present when linking the specific risks with the outcomes.

show abstract

Respiratory failure among patients with COVID-19 in Jiangsu province, China: a multicentre retrospective cohort study

Cited by 2 publications

References 39 publications

Clinical Characteristics of Diabetic Patients with COVID-19 During the Full Liberalization of the Pandemic

Clinical Characteristics of Diabetic Patients with COVID-19 During the Full Liberalization of the Pandemic

Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About